News & Updates

Show Multimedia Only

Addressing unmet needs in mTNBC: Insights on Trop-2–directed ADCs

11 Dec 2025 by

Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer with limited treatment options and historically poor outcomes. Prior to the emergence of antibody–drug conjugates (ADCs), palliative sequential single-agent chemotherapy was the mainstay of treatment for metastatic TNBC (mTNBC), offering limited response and survival. In an interview with MIMS Oncology, Dr Rodrigo Sánchez-Bayona from the Universitary Hospital 12 de Octubre, Madrid, Spain, discussed how Trop-2–targeted ADCs have changed the treatment landscape of mTNBC and predicted their future role in the changing treatment paradigm. He highlighted data on sacituzumab govitecan (SG), an ADC that has demonstrated efficacy regardless of Trop-2 expression status or presence of biomarkers while maintaining quality of life (QoL), and shared a patient case with rapidly progressing mTNBC effectively treated with SG.

Addressing unmet needs in mTNBC: Insights on Trop-2–directed ADCs

11 Dec 2025

Dual IO sets new standard in first-line MSI-H/dMMR mCRC

09 Dec 2025 by

Immune checkpoint inhibitors have substantially improved prognosis of patients with metastatic colorectal cancer (mCRC) characterized by microsatellite instability-high (MSI-H) status or mismatch repair deficiency (dMMR). At an industry-sponsored meeting organized by the Hong Kong Society of Digestive Oncology, Professor Heinz-Josef Lenz of the USC Norris Comprehensive Cancer Center in Los Angeles, California, US, discussed updated results of the phase III CheckMate 8HW trial, which support the paradigm shift in favour of first-line dual immunotherapy (IO) with nivolumab plus ipilimumab vs monotherapy and chemotherapy for patients with MSI-H/dMMR mCRC.

Dual IO sets new standard in first-line MSI-H/dMMR mCRC

09 Dec 2025

Amivantamab plus chemotherapy in a patient with osimertinib-resistant NSCLC with EGFR ex21 L858R mutation

28 Nov 2025 by

A 37-year-old female non-smoker was diagnosed in 2023 with stage IV non-small-cell lung cancer (NSCLC) harbouring EGFR exon 21 L858R mutation. Lymph node (LN), lung and bone metastases were present, and her Eastern Cooperative Oncology Group (ECOG) performance status was 0. Initially, the patient’s response to standard-of-care first-line osimertinib, a third-generation EGFR tyrosine kinase inhibitor (TKI), was good.¹ A PET scan after 6–8 months showed that the metastases had shrunk in response to treatment. However, oligoprogression was also observed at the primary lung tumour site, which was treated with radiotherapy.

Amivantamab plus chemotherapy in a patient with osimertinib-resistant NSCLC with EGFR ex21 L858R mutation

28 Nov 2025

Clinically meaningful benefits and biological clearance of amyloid load after initiating and continuing lecanemab treatment in two patients with Alzheimer’s disease

21 Nov 2025 by

Two Hong Kong patients achieved clinical stabilization along with amyloid burden reduction after ≥12 months of lecanemab treatment.

Clinically meaningful benefits and biological clearance of amyloid load after initiating and continuing lecanemab treatment in two patients with Alzheimer’s disease

21 Nov 2025

Long-term disease control with an FGFR2 inhibitor in advanced cholangiocarcinoma

20 Nov 2025 by

A 69-year-old female diagnosed with localized stage T1b cholangiocarcinoma underwent an extended left hepatectomy with focally involved resection margins in April 2020. Adjuvant therapy was omitted due to prolonged postoperative intra-abdominal sepsis. She remained disease-free until December 2021, when a follow-up CT scan revealed a suspicious 6 mm lesion in liver segments 7/8. A subsequent CT scan in August 2022 showed interval enlargement of the lesion, confirming liver metastasis.

Long-term disease control with an FGFR2 inhibitor in advanced cholangiocarcinoma

20 Nov 2025

Targeting the PI3K/AKT/ PTEN pathway in HR+/HER2- metastatic breast cancer

20 Nov 2025 by

When treating hormone receptor–positive (HR+), HER2-negative (HER2-) metastatic breast cancer (mBC), it is important to target the oestrogen receptor (ER) pathway for as long as the disease remains endocrine-sensitive. In an interview with MIMS Oncology, Dr Shaheenah Dawood, Head of the Oncology Clinical Trials Programme and Director of Oncology Services at Mediclinic City Hospital, Dubai, United Arab Emirates, described how co-targeting both the PI3K/AKT/mTOR and ER pathways with capivasertib and fulvestrant optimizes endocrine therapy (ET) to benefit patients with PIK3CA/AKT1/PTEN-altered HR+/HER2- mBC.

Targeting the PI3K/AKT/ PTEN pathway in HR+/HER2- metastatic breast cancer

20 Nov 2025

Oral gepants: Revolutionizing migraine management in primary care

15 Nov 2025 by

Migraine is a common and debilitating neurological disorder that significantly impacts daily functioning and quality of life (QoL). Despite its high prevalence, migraine remains underdiagnosed and undertreated, particularly in the primary care setting. In an interview with MIMS Doctor, Professor Lawrence Wong, Emeritus Professor of the Department of Medicine and Therapeutics, Chinese University of Hong Kong, highlighted the importance of early diagnosis and timely intervention in migraine management. He noted that calcitonin gene-related peptide (CGRP)–targeted therapies, specifically oral gepants, offer a convenient and effective option for primary care providers (PCPs) to prevent migraine attacks and reduce the long-term burden of the condition.

Oral gepants: Revolutionizing migraine management in primary care

15 Nov 2025

Role of extended adjuvant therapy in minimizing recurrence risk in HR+/HER2+ breast cancer

15 Nov 2025 by

Pathological complete response (pCR) to earlier therapy is one of the key prognostic factors in patients with HER2-positive (HER2+) breast cancer (BC), which can help inform subsequent treatment decisions. In an interview with MIMS Oncology, Dr Joyce Lee, Specialist in Oncology in private practice in Hong Kong, discusses pCR and factors associated with disease recurrence, as well as data supporting the use of neratinib, an irreversible, small-molecule pan-HER tyrosine kinase inhibitor (TKI), as extended adjuvant therapy in hormone receptor– positive (HR+)/HER2+ BC.

Role of extended adjuvant therapy in minimizing recurrence risk in HR+/HER2+ breast cancer

15 Nov 2025

Semaglutide improves cardiorenal outcomes in T2D, regardless of CVD history and baseline BMI

15 Nov 2025

Previous analyses found that body weight reduction does not predict the cardiorenal benefits of glucagon-like peptide-1 receptor agonists (GLP-1 RAs; eg, semaglutide). A pooled post-hoc analysis of the SUSTAIN 6 and PIONEER 6 trials demonstrated that semaglutide improved cardiorenal outcomes in a diverse population of patients with type 2 diabetes (T2D), regardless of prior history of cardiovascular disease (CVD) and baseline body mass index (BMI). The CV benefit remained consistent even when accounting for various degrees of weight loss.

Semaglutide improves cardiorenal outcomes in T2D, regardless of CVD history and baseline BMI

15 Nov 2025

Mepolizumab cuts exacerbation, hospitalization and corticosteroids exposure in a young patient with severe Th2 asthma and marginal BEC level

14 Nov 2025 by

A 36-year-old Caucasian overweight female banker with increasingly severe allergic and asthma symptoms presented to our clinic in late October 2024, after consulting multiple doctors in the US and UK for many years. She had been a smoker since the age of 24 years and switched to vaping 18 months before presentation and was advised to stop smoking. Since a young age, she had frequently experienced shortness of breath on minimal exertion, sports-induced asthma and respiratory tract infections.

Mepolizumab cuts exacerbation, hospitalization and corticosteroids exposure in a young patient with severe Th2 asthma and marginal BEC level

14 Nov 2025

News & Updates

Showing Multidisciplinary articles

Showing

Specialty:

Addressing unmet needs in mTNBC: Insights on Trop-2–directed ADCs

Addressing unmet needs in mTNBC: Insights on Trop-2–directed ADCs

Dual IO sets new standard in first-line MSI-H/dMMR mCRC

Dual IO sets new standard in first-line MSI-H/dMMR mCRC

Amivantamab plus chemotherapy in a patient with osimertinib-resistant NSCLC with EGFR ex21 L858R mutation

Amivantamab plus chemotherapy in a patient with osimertinib-resistant NSCLC with EGFR ex21 L858R mutation

Clinically meaningful benefits and biological clearance of amyloid load after initiating and continuing lecanemab treatment in two patients with Alzheimer’s disease

Clinically meaningful benefits and biological clearance of amyloid load after initiating and continuing lecanemab treatment in two patients with Alzheimer’s disease

Long-term disease control with an FGFR2 inhibitor in advanced cholangiocarcinoma

Long-term disease control with an FGFR2 inhibitor in advanced cholangiocarcinoma

Targeting the PI3K/AKT/ PTEN pathway in HR+/HER2- metastatic breast cancer

Targeting the PI3K/AKT/ PTEN pathway in HR+/HER2- metastatic breast cancer

Oral gepants: Revolutionizing migraine management in primary care

Oral gepants: Revolutionizing migraine management in primary care

Role of extended adjuvant therapy in minimizing recurrence risk in HR+/HER2+ breast cancer

Role of extended adjuvant therapy in minimizing recurrence risk in HR+/HER2+ breast cancer

Semaglutide improves cardiorenal outcomes in T2D, regardless of CVD history and baseline BMI

Semaglutide improves cardiorenal outcomes in T2D, regardless of CVD history and baseline BMI

Mepolizumab cuts exacerbation, hospitalization and corticosteroids exposure in a young patient with severe Th2 asthma and marginal BEC level

Mepolizumab cuts exacerbation, hospitalization and corticosteroids exposure in a young patient with severe Th2 asthma and marginal BEC level